The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology
Journal of Allergy and Clinical Immunology · 2025-01 · 155 (1) · 62-69.e1
DOI: 10.1016/j.jaci.2024.09.031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025-01. Verfasst von Aikaterini Anagnostou und 16 weiteren Autor:innen. Beteiligte Einrichtung: Texas Children's Hospital, Department of Allergy and Immunology, Houston, Tex. Hauptthemen laut MEDLINE: Omalizumab, Food Hypersensitivity, Anti-Allergic Agents. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Omalizumab was recently approved by the US Food and Drug Administration for treatment of any single food allergy or multiple food allergies in children aged 1 year and older and adults. There is currently no formal guidance regarding recommended best practices for omalizumab use in food allergy, including patient selection, anticipated goals and outcomes of therapy, procedure for monitoring patients who elect to start omalizumab therapy, and ways in which omalizumab can be incorporated into the landscape of food allergy management and daily clinical practice. This work group report was developed by the food allergy therapies subcommittee of the Adverse Reactions to Foods Committee within the American Academy of Allergy, Asthma & Immunology. Consensus, evidence-based guidance regarding experts' recommendations for using omalizumab to treat children and adults with food allergy was developed by using modified Delphi methodology. In iterative fashion, a total of 8 statements regarding how to use omalizumab to treat patients with food allergy were developed by 16 clinical experts. This guidance provides the clinician with a suggested approach to patient selection, initiation of therapy, monitoring of efficacy, and long-term follow-up care. The role of preference-sensitive care is emphasized, with most statements offering care recommendations relevant to the culture and values of a particular practice setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Texas Children's Hospital, Department of Allergy and Immunology, Houston, Tex.
- Department of Pediatrics, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, Tex.
- Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Palo Alto, Calif.
- Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
- Section of Allergy and Clinical Immunology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo.
- Division of Allergy and Immunology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC.
Förderung
- NIAID NIH HHS
Zitieren
APA
Anagnostou, A., Bird, J. A., Chinthrajah, S., Dribin, T. E., Fleischer, D. M., Kim, E., Nowak-Wegrzyn, A., Rachid, R., Shaker, M. S., Shreffler, W., Sicherer, S., Tam, J., Vickery, B. P., Virkud, Y. V., Wang, J., Young, M., & Greenhawt, M. (2025). The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology. Journal of Allergy and Clinical Immunology, 155(1), 62-69.e1. https://doi.org/10.1016/j.jaci.2024.09.031
Vancouver
Anagnostou A, Bird JA, Chinthrajah S, Dribin TE, Fleischer DM, Kim E, et al. The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology. Journal of Allergy and Clinical Immunology. 2025;155(1):62-69.e1. doi:10.1016/j.jaci.2024.09.031
BibTeX
@article{Anagnostou2025,
author = {Anagnostou, Aikaterini and Bird, J Andrew and Chinthrajah, Sharon and Dribin, Timothy E and Fleischer, David M and Kim, Edwin and Nowak-Wegrzyn, Anna and Rachid, Rima and Shaker, Marcus S and Shreffler, Wayne and Sicherer, Scott and Tam, Jonathan and Vickery, Brian P and Virkud, Yamini V and Wang, Julie and Young, Michael and Greenhawt, Matthew},
title = {The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology},
journal = {Journal of Allergy and Clinical Immunology},
year = {2025},
volume = {155},
number = {1},
pages = {62--69.e1},
doi = {10.1016/j.jaci.2024.09.031}
}
EUVIMED